An applied guide to pharmacogenetics for the practicing neurologist — covering CYP450 enzyme genetics, drug-gene interactions relevant to antiepileptic and neuropsychiatric drug therapy, HLA-associated hypersensitivity reactions, and the clinical implementation of pharmacogenetic testing.
Tags: Neurogenetics · Advanced
Pharmacogenetics is the study of how genetic variation influences drug response — affecting absorption, distribution, metabolism, excretion (ADME), and pharmacodynamic drug targets. Genetic variants in drug-metabolizing enzymes alter plasma drug concentrations, creating a spectrum from toxicity (impaired metabolism → drug accumulation) to therapeutic failure (ultra-rapid metabolism → subtherapeutic levels). The major clinical phenotypes are: poor metabolizer (PM), intermediate metabolizer (IM), normal/extensive metabolizer (NM/EM), and ultra-rapid metabolizer (UM).
Key Points
Four CYP450 enzymes are most important for neurological drugs: CYP2C9 (phenytoin, valproate, losartan), CYP2C19 (clopidogrel, clobazam, diazepam, omeprazole), CYP2D6 (tricyclics, opioids, atomoxetine, antipsychotics), and CYP3A4/5 (carbamazepine, oxcarbazepine, statins). Polymorphisms in these enzymes are common — CYP2D6 PM phenotype affects ~7–10% of Europeans; CYP2C19 PM affects ~2–5% of Europeans but up to 15–20% of Asians.
Key Points
Certain HLA alleles confer high risk of severe immune-mediated drug hypersensitivity reactions — Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). Neurologists prescribe several drugs with well-characterized HLA associations. Pre-prescription HLA testing prevents severe, potentially fatal adverse reactions.
Key Points
Antiepileptic drug (AED) pharmacogenomics encompasses both pharmacokinetic (drug metabolism) and pharmacodynamic (drug target) genetic variation. SCN1A variants that reduce sodium channel sensitivity may explain resistance to sodium channel-blocking AEDs. UGT enzymes metabolize lamotrigine and valproate. POLG mutations contraindicate valproate use. These interactions have direct clinical management implications.
Key Points
Pharmacogenetic testing is increasingly available as preemptive panels that genotype multiple clinically actionable variants before drug prescribing is needed. Implementation requires understanding how to interpret multi-gene reports, recognizing the limitations of current evidence, and integrating results with clinical context. Several health systems have implemented preemptive pharmacogenomics as part of precision medicine initiatives.
Key Points
1. A woman with epilepsy well-controlled on lamotrigine 300 mg/day becomes pregnant. Her seizure control begins to deteriorate in the second trimester. The pharmacogenetic principle underlying this is:
Lamotrigine is primarily metabolized by glucuronidation via UGT1A4. During pregnancy, rising estrogen levels induce UGT1A4 activity, dramatically increasing lamotrigine clearance. Lamotrigine levels can decrease by 40–60% during pregnancy, leading to breakthrough seizures despite a previously stable dose. Frequent serum lamotrigine level monitoring is essential during pregnancy, and doses may need to double or triple. This interaction is one of the most clinically important drug-gene-state interactions in women with epilepsy.
2. A patient is found to be a CYP2D6 ultra-rapid metabolizer (UM). She is started on nortriptyline for chronic pain. The pharmacogenetic concern is:
CYP2D6 ultra-rapid metabolizers (UMs) metabolize CYP2D6 substrates much faster than normal, resulting in subtherapeutic plasma drug concentrations at standard doses. For nortriptyline (a tricyclic antidepressant metabolized primarily by CYP2D6), UM status leads to insufficient drug exposure and treatment failure. CPIC recommends using an alternative antidepressant not metabolized by CYP2D6 (e.g., citalopram, escitalopram) for UMs to avoid unpredictable dosing.
3. A Han Chinese patient with new-onset epilepsy is being considered for carbamazepine. The FDA-recommended screening test before prescribing is:
HLA-B*15:02 is strongly associated with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Southeast Asian populations (Han Chinese, Thai, Malaysian). The FDA requires HLA-B*15:02 testing before starting carbamazepine/oxcarbazepine in patients of Asian ancestry due to the markedly elevated risk (~25-fold increase). The allele is rare in European-ancestry patients (<0.1%), so testing is not required for European populations.
4. A child with Dravet syndrome (heterozygous SCN1A loss-of-function variant) continues to have breakthrough seizures. The parent asks about lamotrigine, which helped a friend's child with epilepsy. The appropriate response is:
Dravet syndrome is caused by SCN1A haploinsufficiency (loss of Nav1.1 function). Sodium channel-blocking AEDs — particularly oxcarbazepine and lamotrigine, which are commonly prescribed — further reduce Nav1.1 activity and can paradoxically worsen seizures, potentially precipitating status epilepticus. This is one of the most critical pharmacogenomic drug contraindications in neurology. Appropriate agents for Dravet syndrome include valproate, clobazam, stiripentol, fenfluramine, and cannabidiol.
5. A 2-year-old with developmental regression and suspected mitochondrial disease is being considered for valproate for new seizures. Which assessment is most critical before prescribing?
POLG (mitochondrial DNA polymerase gamma) mutations cause Alpers syndrome and related POLG-spectrum disorders. In these patients, valproate causes fulminant hepatotoxicity (liver failure) and neurological deterioration, often fatal. Any child with developmental regression, suspected mitochondrial disease, or features of Alpers syndrome (refractory seizures, hepatic involvement, cortical neurodegeneration) must be evaluated for POLG mutations before valproate is considered. This is the most critical drug contraindication in pediatric neurology.